Philadelphia chromosome positive acute lymphoblastic leukaemia
FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers
The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate
Novartis’ Scemblix granted FDA accelerated approval in newly diagnosed CML
Approximately 9,280 new cases of the disease are expected to be diagnosed in the US this year
Takeda’s Iclusig combination granted FDA accelerated approval for rare form of leukaemia
The drug is now the first targeted therapy approved as a frontline treatment for Ph-positive ALL
Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia
More than 6,300 people are diagnosed with the disease every year in Europe
Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
Approximately 18,740 new cases of CLL have been diagnosed in the US this year
Amgen’s supplemental Biologics License Application for Blincyto approved by FDA
The approval for the leukaemia drug was supported by additional data from two phase 3 studies
Sanofi and Innate Pharma expand cancer therapeutics collaboration
The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology
ICR twin study indicates childhood leukaemia begins in the womb
The study, published in Leukemia, will help clinicians advise parents of twins with ALL
NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
The recommendation makes Scemblix the first treatment in its class to be authorised in Britain
Daiichi gets breakthrough status for pre-NDA leukaemia drug
Quizartinib could have an advantage over rival drug Rydapt
NICE to look again at Pfizer’s Besponsa after appeal
The blood cancer medicine was originally turned down on cost-effectiveness grounds
